TY - JOUR
T1 - Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for Esophageal Adenocarcinoma
T2 - Results from a large multicenter cohort
AU - Gaddam, Srinivas
AU - Singh, Mandeep
AU - Balasubramanian, Gokulakrishnan
AU - Thota, Prashanthi
AU - Gupta, Neil
AU - Wani, Sachin
AU - Higbee, April D.
AU - Mathur, Sharad C.
AU - Horwhat, John D.
AU - Rastogi, Amit
AU - Young, Patrick E.
AU - Cash, Brooks D.
AU - Bansal, Ajay
AU - Vargo, John J.
AU - Falk, Gary W.
AU - Lieberman, David A.
AU - Sampliner, Richard E.
AU - Sharma, Prateek
N1 - Funding Information:
Funding Supported by the Veterans Affairs Medical Center (Kansas City, MO).
PY - 2013/9
Y1 - 2013/9
N2 - Background & Aims Recent population-based studies have shown a low risk of esophageal adenocarcinoma (EAC) in patients with nondysplastic Barrett's esophagus (NDBE). We evaluated whether persistence of NDBE over multiple consecutive surveillance endoscopic examinations could be used in risk stratification of patients with Barrett's esophagus (BE). Methods We performed a multicenter outcomes study of a large cohort of patients with BE. Based on the number of consecutive surveillance endoscopies showing NDBE, we identified 5 groups of patients. Patients in group 1 were found to have NDBE at their first esophagogastroduodenoscopy (EGD). Patients in group 2 were found to have NDBE on their first 2 consecutive EGDs. Similarly, patients in groups 3, 4, and 5 were found to have NDBE on 3, 4, and 5 consecutive surveillance EGDs. A logistic regression model was built to determine whether persistence of NDBE independently protected against development of cancer. Results Of a total of 3515 patients with BE, 1401 patients met the inclusion criteria (93.3% white; 87.5% men; median age, 60 ±17 years). The median follow-up period was 5 ± 3.9 years (7846 patient-years). The annual risk of EAC in groups 1 to 5 was 0.32%, 0.27%, 0.16%, 0.2%, and 0.11%, respectively (P for trend =.03). After adjusting for age, sex, and length of BE, persistence of NDBE, based on multiple surveillance endoscopies, was associated with a gradually lower likelihood of progression to EAC. Conclusions Persistence of NDBE over several endoscopic examinations identifies patients who are at low risk for development of EAC. These findings support lengthening surveillance intervals or discontinuing surveillance of patients with persistent NDBE.
AB - Background & Aims Recent population-based studies have shown a low risk of esophageal adenocarcinoma (EAC) in patients with nondysplastic Barrett's esophagus (NDBE). We evaluated whether persistence of NDBE over multiple consecutive surveillance endoscopic examinations could be used in risk stratification of patients with Barrett's esophagus (BE). Methods We performed a multicenter outcomes study of a large cohort of patients with BE. Based on the number of consecutive surveillance endoscopies showing NDBE, we identified 5 groups of patients. Patients in group 1 were found to have NDBE at their first esophagogastroduodenoscopy (EGD). Patients in group 2 were found to have NDBE on their first 2 consecutive EGDs. Similarly, patients in groups 3, 4, and 5 were found to have NDBE on 3, 4, and 5 consecutive surveillance EGDs. A logistic regression model was built to determine whether persistence of NDBE independently protected against development of cancer. Results Of a total of 3515 patients with BE, 1401 patients met the inclusion criteria (93.3% white; 87.5% men; median age, 60 ±17 years). The median follow-up period was 5 ± 3.9 years (7846 patient-years). The annual risk of EAC in groups 1 to 5 was 0.32%, 0.27%, 0.16%, 0.2%, and 0.11%, respectively (P for trend =.03). After adjusting for age, sex, and length of BE, persistence of NDBE, based on multiple surveillance endoscopies, was associated with a gradually lower likelihood of progression to EAC. Conclusions Persistence of NDBE over several endoscopic examinations identifies patients who are at low risk for development of EAC. These findings support lengthening surveillance intervals or discontinuing surveillance of patients with persistent NDBE.
KW - Barrett's Esophagus
KW - Dysplasia
KW - Esophageal Adenocarcinoma
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=84883170964&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2013.05.040
DO - 10.1053/j.gastro.2013.05.040
M3 - Article
AN - SCOPUS:84883170964
SN - 0016-5085
VL - 145
SP - 548-553.e1
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -